Emerging Research

Pemvidutide

GLP & Metabolic · ALT-801

An investigational GLP-1 and glucagon receptor dual agonist peptide studied in preclinical liver models and clinical metabolic research.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Research Level

Emerging Research

Browse the store →

🧬

Pemvidutide (ALT-801) is an investigational synthetic peptide engineered as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor, under development by Altimmune. The dual mechanism is described in the literature as combining GLP-1-mediated appetite signaling with glucagon-mediated effects on energy expenditure and hepatic lipid metabolism.

It remains investigational and has been evaluated in preclinical models of steatohepatitis and in phase 2 clinical research in overweight and obesity populations.

Pemvidutide co-activates the GLP-1 and glucagon receptors, both class B GPCRs. Study reports describe GLP-1 receptor engagement with appetite and glycemic signaling, while glucagon-receptor activity is investigated for its proposed contribution to energy expenditure and to hepatic fat metabolism [1].

Researchers frame the dual-agonist design as intended to balance the two receptor activities within a single molecule.

Dual incretin/glucagon signaling - studied for combined GLP-1 and glucagon receptor agonism [1][2].
Hepatic lipid models - investigated in a translational NASH mouse model [1].
Body-weight research - examined in a placebo-controlled phase 2 obesity trial [2].
Serum lipid measures - reported as study endpoints in clinical research [2].

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

In a translational mouse model of non-alcoholic steatohepatitis, investigators administered ALT-801 and reported effects on hepatic steatosis and related metabolic measures compared with controls [1].

In the 48-week, placebo-controlled phase 2 MOMENTUM trial, researchers randomized non-diabetic subjects with overweight or obesity to weekly pemvidutide (1.2, 1.8, or 2.4 mg) or placebo and reported mean body-weight changes and reductions in liver-fat measures across dose groups [2].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

RetatrutideNeutral

Both are multi-receptor metabolic agonists in the investigational pipeline; studied comparatively, not combined.

SemaglutideNeutral

GLP-1 receptor agonist reference compound; compared within the class.

CagrilintideNeutral

Amylin-analog studied in separate combination research; no established co-use data with pemvidutide.

What receptors does pemvidutide target?

Research describes it as a dual agonist of the GLP-1 and glucagon receptors [1][2].

What is its development stage?

It is investigational, studied in preclinical liver models and phase 2 clinical research [1][2].

Is this product intended for human use?

No. This entry is for research and informational purposes only and is not dosing guidance or a therapeutic recommendation.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.